scholarly journals Rare causes of stroke in young people

Author(s):  
S. Borzenkov ◽  
N. Svyrydova ◽  
L. Borzenkova

One of the reasons that can lead to a stroke in young people is Fabry’s disease. This is one of the rare, genetically determined diseases of the X – linked type of inheritance, belonging to the group of lysosomal diseases of accumulation (synonyms: diffuse universal angiokeratoma, hereditary dystonic lipidosis, deficiency of alpha galactosidase A). The genetics of Fabry disease is due to mutations in the GLA gene characterized by a significant decrease in the activity or absence of the enzyme α-galactosidase A. These deviations result in the accumulation of glycosphingolipids, namely, ceramide accumulated in the cytoplasm or lysosomes of cells of various organs and tissues, disrupting their function, causing ischemia and tissue fibrosis. A specific laboratory diagnosis is the determination of the activity of alpha-galactosidase A. In Fabry’s disease, the activity of alpha-galactosidase A in men in men is always reduced, and in women, the activity of GLA may be near the lower limit of norm, or slightly lower, or normal. In Fabry disease symptomatic therapy and enzyme replacement therapy are used to reduce the severity and prevent the symptoms of Fabry disease. Antiplatelet therapy should be the basis of treatment. With timely access to enzyme replacement therapy, the prognosis is favorable.

The Lancet ◽  
2010 ◽  
Vol 375 (9725) ◽  
pp. 1523 ◽  
Author(s):  
Stephen Waldek ◽  
Dominique P Germain ◽  
Christoph Wanner ◽  
David G Warnock

2007 ◽  
Vol 35 (4) ◽  
pp. 574-581 ◽  
Author(s):  
K Tsuboi

Fabry's disease, a disorder affecting the gene for the lysosomal enzyme α-galactosidase A (α-GAL A), can cause accumulation of globotriaosylceramide (GL-3) in the vascular endothelial cells. Symptoms include pain, angiokeratoma, corneal clouding, and damage to the heart and kidneys. Human recombinant α-GAL A for use as an enzyme replacement therapy was launched in Japan in April 2004. Eleven ambulatory patients with Fabry's disease were given replacement α-GAL A therapy. Three patients died due to factors associated with Fabry's disease. The enzyme replacement therapies in the remaining eight patients continued safely without any notable adverse events. The following were observed: a lowering of the plasma levels of GL-3 in seven cases, an improvement in the daily activities in six cases, and a reduction in corneal clouding in three cases. Although careful observation is necessary, these results suggest that replacement α-GAL A therapy may be a safe and effective treatment of Fabry's disease.


2010 ◽  
Vol 43 (1) ◽  
pp. 99-103
Author(s):  
Teruko Nakamura ◽  
Yukari Yamashita ◽  
Yoshiyuki Tomiyoshi ◽  
Shuichi Rikitake ◽  
Tomoya Kishi ◽  
...  

2004 ◽  
Vol 66 (2) ◽  
pp. 158-165 ◽  
Author(s):  
L Spinelli ◽  
A Pisani ◽  
M Sabbatini ◽  
M Petretta ◽  
MV Andreucci ◽  
...  

2009 ◽  
Vol 71 (05) ◽  
pp. 550-556 ◽  
Author(s):  
S. Hirashio ◽  
T. Taguchi ◽  
T. Naito ◽  
K. Maki ◽  
S. Ogata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document